Literature DB >> 3547668

Current status of adjuvant chemotherapy for breast cancer.

G Bonadonna, P Valagussa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3547668

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  9 in total

Review 1.  Choosing quality of care measures based on the expected impact of improved care on health.

Authors:  A L Siu; E A McGlynn; H Morgenstern; M H Beers; D M Carlisle; E B Keeler; J Beloff; K Curtin; J Leaning; B C Perry
Journal:  Health Serv Res       Date:  1992-12       Impact factor: 3.402

Review 2.  Breast cancer. Advances in management.

Authors:  G N Brodie; A Elefanty
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

3.  Prognosis of common cancers.

Authors:  P H Geggie
Journal:  Can Fam Physician       Date:  1990-05       Impact factor: 3.275

4.  Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization (TAE) treated patients with resectable or non-resectable hepatocellular carcinoma. Osaka Study Group on Hepatocellular Carcinoma.

Authors: 
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  The Canadian experience with intensive fluorouracil, epirubicin and cyclophosphamide in patients with early stage breast cancer.

Authors:  M N Levine; V Bramwell; K Pritchard; D Perrault; B Findlay; H Abu-Zahra; D Warr; A Arnold; J Skillings
Journal:  Drugs       Date:  1993       Impact factor: 9.546

6.  Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinoma.

Authors:  G Gasparini; S Dal Fior; F Pozza; P Bevilacqua
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

7.  Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer.

Authors:  P F Bruning; M J Pit; M de Jong-Bakker; A van den Ende; A Hart; A van Enk
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

8.  The cost of breast cancer recurrences.

Authors:  S F Hurley; R M Huggins; R D Snyder; J F Bishop
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

9.  Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup.

Authors:  S Nicholson; J Richard; C Sainsbury; P Halcrow; P Kelly; B Angus; C Wright; J Henry; J R Farndon; A L Harris
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.